HRS announces quality improvement program for atrial fibrillation and stroke prevention

The Heart Rhythm Society (HRS) announced it would award up to $500,000 in grants for atrial fibrillation and stroke prevention research aimed at addressing National Quality Improvement priorities.

Boehringer Ingelheim Pharmaceuticals is partnering with HRS on the initiative. Applications are due on April 18 and can be accessed through a website.

HRS members will evaluate applications between April 19 and April 26 and will choose up to six finalists for the award. The finalists will present their proposals to an expert panel during Heart Rhythm 2016 in San Francisco on May 5. The winners will present their data at Heart Rhythm 2017 in Chicago.

Proposals should address demonstration projects or research that examine improving risk screening and management of patients 18 years and older who have been diagnosed with non-valvular atrial fibrillation and are at risk for ischemic stroke.

The proposals should include at least one of the following topic areas: healthcare provider education; health populations and improvement; prevention/treatment; healthcare provider and patient dialog and shared decision-making; cost reduction; team-based coordination of care; family-centered care and patient satisfaction; and communication.